{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Fetching data from: https://clinicaltrials.gov/api/v2/studies?query.term=Bitopertin&pageSize=100\n",
      "Fetching data from: https://clinicaltrials.gov/api/v2/studies?query.term=GSBR-1290&pageSize=100\n",
      "Fetching data from: https://clinicaltrials.gov/api/v2/studies?query.term=RP-1&pageSize=100\n",
      "Fetching data from: https://clinicaltrials.gov/api/v2/studies?query.term=Ritlecitinib&pageSize=100\n",
      "Fetching data from: https://clinicaltrials.gov/api/v2/studies?query.term=MK-0616&pageSize=100\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>NCT ID</th>\n",
       "      <th>Asset</th>\n",
       "      <th>Title</th>\n",
       "      <th>Lead Sponsor</th>\n",
       "      <th>Acronym</th>\n",
       "      <th>Overall Status</th>\n",
       "      <th>Enrollment</th>\n",
       "      <th>Start Date</th>\n",
       "      <th>Conditions</th>\n",
       "      <th>Interventions</th>\n",
       "      <th>Primary Outcome(s)</th>\n",
       "      <th>Secondary Outcome(s)</th>\n",
       "      <th>Locations</th>\n",
       "      <th>Primary Completion Date</th>\n",
       "      <th>Study First Post Date</th>\n",
       "      <th>Last Update Post Date</th>\n",
       "      <th>Study Type</th>\n",
       "      <th>Phases</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT01636492</td>\n",
       "      <td>Bitopertin</td>\n",
       "      <td>Single Oral Ascending Dose Study of Safety, To...</td>\n",
       "      <td>Hoffmann-La Roche</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>71</td>\n",
       "      <td>2005-11</td>\n",
       "      <td>Healthy Volunteer</td>\n",
       "      <td>bitopertin, placebo</td>\n",
       "      <td>Safety: Incidence of adverse events</td>\n",
       "      <td>Pharmacokinetics: Area under the concentration...</td>\n",
       "      <td>Christchurch - New Zealand</td>\n",
       "      <td>2006-08</td>\n",
       "      <td>2012-07-10</td>\n",
       "      <td>2016-11-02</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT05308472</td>\n",
       "      <td>Bitopertin</td>\n",
       "      <td>(AURORA) A Randomized, Double-blind, Placebo-C...</td>\n",
       "      <td>Disc Medicine, Inc</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>ACTIVE_NOT_RECRUITING</td>\n",
       "      <td>75</td>\n",
       "      <td>2022-10-31</td>\n",
       "      <td>Erythropoietic Protoporphyria</td>\n",
       "      <td>DISC-1459, DISC-1459, Placebo, DISC-1459</td>\n",
       "      <td>Percent change from baseline in whole blood me...</td>\n",
       "      <td>Total hours of sunlight exposure to skin on da...</td>\n",
       "      <td>Birmingham - United States, San Francisco - Un...</td>\n",
       "      <td>2024-02-20</td>\n",
       "      <td>2022-04-04</td>\n",
       "      <td>2024-04-15</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT01192880</td>\n",
       "      <td>Bitopertin</td>\n",
       "      <td>A Phase III, Multi-Center, Randomized, 24 Week...</td>\n",
       "      <td>Hoffmann-La Roche</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>625</td>\n",
       "      <td>2010-11</td>\n",
       "      <td>Schizophrenia</td>\n",
       "      <td>Placebo, Bitopertin, Antipsychotics</td>\n",
       "      <td>Mean Change From Baseline in the Positive and ...</td>\n",
       "      <td>Mean Change from Baseline in the Personal and ...</td>\n",
       "      <td>Costa Mesa - United States, Escondido - United...</td>\n",
       "      <td>2014-07</td>\n",
       "      <td>2010-09-01</td>\n",
       "      <td>2017-02-15</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT05883748</td>\n",
       "      <td>Bitopertin</td>\n",
       "      <td>An Open-Label, Long-Term Study to Investigate ...</td>\n",
       "      <td>Disc Medicine, Inc</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>ENROLLING_BY_INVITATION</td>\n",
       "      <td>200</td>\n",
       "      <td>2023-08-31</td>\n",
       "      <td>Erythropoietic Protoporphyria</td>\n",
       "      <td>DISC-1459, DISC-1459</td>\n",
       "      <td>Incidence of treatment-emergent adverse events...</td>\n",
       "      <td>Change from baseline in daily daylight toleran...</td>\n",
       "      <td>Birmingham - United States, San Francisco - Un...</td>\n",
       "      <td>2028-06</td>\n",
       "      <td>2023-06-01</td>\n",
       "      <td>2024-02-22</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2, PHASE3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT02019290</td>\n",
       "      <td>Bitopertin</td>\n",
       "      <td>A SINGLE CENTER, OPEN LABEL, FIXED SEQUENCE ST...</td>\n",
       "      <td>Hoffmann-La Roche</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>WITHDRAWN</td>\n",
       "      <td>0</td>\n",
       "      <td>2014-02-10</td>\n",
       "      <td>Healthy Volunteer</td>\n",
       "      <td>Midazolam, bitopertin</td>\n",
       "      <td>Change in plasma area under the concentration-...</td>\n",
       "      <td>Change in 1'-hydroxymidazolam plasma AUC after...</td>\n",
       "      <td>No locations listed</td>\n",
       "      <td>2014-03-31</td>\n",
       "      <td>2013-12-24</td>\n",
       "      <td>2017-10-25</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>NCT05828108</td>\n",
       "      <td>Bitopertin</td>\n",
       "      <td>A Phase I/II, Intra-Patient Dose-Escalation St...</td>\n",
       "      <td>National Heart, Lung, and Blood Institute (NHLBI)</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>30</td>\n",
       "      <td>2023-07-25</td>\n",
       "      <td>Steroid-refractory Diamond-Blackfan Anemia (DBA)</td>\n",
       "      <td>Bitopertin</td>\n",
       "      <td>Rate of response</td>\n",
       "      <td>Rate of relapse, Long-term safety of drug, Tol...</td>\n",
       "      <td>Bethesda - United States</td>\n",
       "      <td>2029-05-01</td>\n",
       "      <td>2023-04-25</td>\n",
       "      <td>2024-04-10</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>NCT03271541</td>\n",
       "      <td>Bitopertin</td>\n",
       "      <td>A Phase II, Single Arm, Multicenter, Proof-of-...</td>\n",
       "      <td>Hoffmann-La Roche</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>12</td>\n",
       "      <td>2017-10-26</td>\n",
       "      <td>Beta-Thalassemia</td>\n",
       "      <td>Bitopertin</td>\n",
       "      <td>Safety Outcome: Percentage of Participants wit...</td>\n",
       "      <td>Apparent Clearance of Bitopertin, Volume of Di...</td>\n",
       "      <td>Genova - Italy, Milano - Italy, Baabda - Leban...</td>\n",
       "      <td>2018-06-29</td>\n",
       "      <td>2017-09-05</td>\n",
       "      <td>2018-10-05</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>NCT01192906</td>\n",
       "      <td>Bitopertin</td>\n",
       "      <td>A Phase III, Multi-center, Randomized, 24 Week...</td>\n",
       "      <td>Hoffmann-La Roche</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>624</td>\n",
       "      <td>2010-12</td>\n",
       "      <td>Schizophrenia</td>\n",
       "      <td>Placebo, bitopertin [RO4917838], bitopertin [R...</td>\n",
       "      <td>Efficacy (PANSS negative symptoms factor score...</td>\n",
       "      <td>No secondary outcomes listed</td>\n",
       "      <td>Carson - United States, Oceanside - United Sta...</td>\n",
       "      <td>2014-07</td>\n",
       "      <td>2010-09-01</td>\n",
       "      <td>2016-11-02</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>NCT01234779</td>\n",
       "      <td>Bitopertin</td>\n",
       "      <td>A Phase II, Multi-center, Randomized, 4-week, ...</td>\n",
       "      <td>Hoffmann-La Roche</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>301</td>\n",
       "      <td>2011-02</td>\n",
       "      <td>Schizophrenia</td>\n",
       "      <td>bitopertin [RO4917838], bitopertin [RO4917838]...</td>\n",
       "      <td>Change in Positive and Negative Syndrome Scale...</td>\n",
       "      <td>Clinical response, defined as at least 30% or ...</td>\n",
       "      <td>Little Rock - United States, Cerritos - United...</td>\n",
       "      <td>2012-09</td>\n",
       "      <td>2010-11-04</td>\n",
       "      <td>2016-11-02</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>NCT01235559</td>\n",
       "      <td>Bitopertin</td>\n",
       "      <td>Phase III, Multi-center, Randomized, 12-week, ...</td>\n",
       "      <td>Hoffmann-La Roche</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>604</td>\n",
       "      <td>2010-12</td>\n",
       "      <td>Schizophrenia</td>\n",
       "      <td>Placebo, bitopertin [RO4917838] level 1, bitop...</td>\n",
       "      <td>Positive symptoms factor score assessed by Pos...</td>\n",
       "      <td>Symptom domains of schizophrenia using Positiv...</td>\n",
       "      <td>Costa Mesa - United States, Escondido - United...</td>\n",
       "      <td>2015-03</td>\n",
       "      <td>2010-11-05</td>\n",
       "      <td>2016-11-02</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>NCT01235585</td>\n",
       "      <td>Bitopertin</td>\n",
       "      <td>Phase III, Multi-center, Randomized, 12-week, ...</td>\n",
       "      <td>Hoffmann-La Roche</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>597</td>\n",
       "      <td>2010-12</td>\n",
       "      <td>Schizophrenia</td>\n",
       "      <td>Placebo, bitopertin [RO4917838], bitopertin [R...</td>\n",
       "      <td>Positive symptoms factor score assessed by Pos...</td>\n",
       "      <td>Symptom domains of schizophrenia using Positiv...</td>\n",
       "      <td>Carson - United States, Garden Grove - United ...</td>\n",
       "      <td>2014-09</td>\n",
       "      <td>2010-11-05</td>\n",
       "      <td>2016-11-02</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>NCT01674361</td>\n",
       "      <td>Bitopertin</td>\n",
       "      <td>A Phase II, Multicenter, Randomized, Double-Bl...</td>\n",
       "      <td>Hoffmann-La Roche</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>99</td>\n",
       "      <td>2012-12-31</td>\n",
       "      <td>Obsessive-Compulsive Disorder</td>\n",
       "      <td>Bitopertin, Placebo, SSRI</td>\n",
       "      <td>Change From Baseline in Total Score on Yale-Br...</td>\n",
       "      <td>Change From Baseline in Clinical Global Impres...</td>\n",
       "      <td>Oceanside - United States, Stanford - United S...</td>\n",
       "      <td>2015-04-30</td>\n",
       "      <td>2012-08-28</td>\n",
       "      <td>2017-08-02</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>NCT06139055</td>\n",
       "      <td>GSBR-1290</td>\n",
       "      <td>A 2-part, Phase 1, Randomized Study to Evaluat...</td>\n",
       "      <td>Gasherbrum Bio, Inc</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>ACTIVE_NOT_RECRUITING</td>\n",
       "      <td>70</td>\n",
       "      <td>2023-10-02</td>\n",
       "      <td>Healthy Volunteers</td>\n",
       "      <td>GSBR-1290 (Capsule/Tablet), GSBR-1290, Placebo...</td>\n",
       "      <td>Part 1: Analysis of Maximum Observed Plasma Co...</td>\n",
       "      <td>Part 1: Number of Participants With Adverse Ev...</td>\n",
       "      <td>Miami - United States, Miami - United States, ...</td>\n",
       "      <td>2024-03</td>\n",
       "      <td>2023-11-18</td>\n",
       "      <td>2024-02-15</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>NCT05893043</td>\n",
       "      <td>GSBR-1290</td>\n",
       "      <td>A Phase 1, Randomized, Double-blind, Placebo-c...</td>\n",
       "      <td>Gasherbrum Bio, Inc</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>18</td>\n",
       "      <td>2023-04-24</td>\n",
       "      <td>Healthy Volunteers</td>\n",
       "      <td>GSBR-1290, Placebo</td>\n",
       "      <td>Number of Participants With Adverse Events (AE...</td>\n",
       "      <td>Analysis of Maximum Observed Plasma Concentrat...</td>\n",
       "      <td>Anaheim - United States</td>\n",
       "      <td>2023-06-28</td>\n",
       "      <td>2023-06-07</td>\n",
       "      <td>2023-07-14</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>NCT05762471</td>\n",
       "      <td>GSBR-1290</td>\n",
       "      <td>A Phase 1b/2a, Randomized, Double-blind, Place...</td>\n",
       "      <td>Gasherbrum Bio, Inc</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>142</td>\n",
       "      <td>2023-01-09</td>\n",
       "      <td>Overweight or Obesity, Type2 Diabetes Mellitus</td>\n",
       "      <td>GSBR-1290, Placebo</td>\n",
       "      <td>Incidence, severity and relationship of AE/SAE...</td>\n",
       "      <td>Analysis of Cmax at specified timepoints predo...</td>\n",
       "      <td>Anaheim - United States, Chula Vista - United ...</td>\n",
       "      <td>2024-04-11</td>\n",
       "      <td>2023-03-09</td>\n",
       "      <td>2024-04-25</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>NCT02709876</td>\n",
       "      <td>RP-1</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>Stem Cells Arabia</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>UNKNOWN</td>\n",
       "      <td>50</td>\n",
       "      <td>2014-04</td>\n",
       "      <td>Retinitis Pigmentosa</td>\n",
       "      <td>Stem Cell Transplantation</td>\n",
       "      <td>ETDRS Visual acuity change</td>\n",
       "      <td>Quality of Life: Questionnaire VFQ-25 (Visual ...</td>\n",
       "      <td>Amman - Jordan</td>\n",
       "      <td>2020-09</td>\n",
       "      <td>2016-03-16</td>\n",
       "      <td>2020-03-17</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>NCT04776889</td>\n",
       "      <td>RP-1</td>\n",
       "      <td>The Prognosis of Lipid Reprogramming With the ...</td>\n",
       "      <td>National Cancer Institute, Egypt</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>70</td>\n",
       "      <td>2019-01-15</td>\n",
       "      <td>Prostate Cancer Metastatic</td>\n",
       "      <td>Rosuvastatin 20mg, surgical castration</td>\n",
       "      <td>Lipid profile, Aggressiveness parameters, Aggr...</td>\n",
       "      <td>short-term clinical outcome, short-term clinic...</td>\n",
       "      <td>Cairo - Egypt</td>\n",
       "      <td>2020-12-30</td>\n",
       "      <td>2021-03-02</td>\n",
       "      <td>2021-03-02</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE4</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>NCT06264180</td>\n",
       "      <td>RP-1</td>\n",
       "      <td>Randomized, Ph3 Clinical Study Comparing Vusol...</td>\n",
       "      <td>Replimune Inc.</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>NOT_YET_RECRUITING</td>\n",
       "      <td>400</td>\n",
       "      <td>2024-06-01</td>\n",
       "      <td>Advanced Melanoma</td>\n",
       "      <td>Vusolimogene Oderparepvec, Nivolumab, Nivoluma...</td>\n",
       "      <td>Overall Survival (OS)</td>\n",
       "      <td>Progression Free Survival (PFS), Objective Res...</td>\n",
       "      <td>No locations listed</td>\n",
       "      <td>2029-01-01</td>\n",
       "      <td>2024-02-16</td>\n",
       "      <td>2024-02-16</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>NCT05858229</td>\n",
       "      <td>RP-1</td>\n",
       "      <td>A Phase 1B Study of Intralesional Injection of...</td>\n",
       "      <td>Sherrif Ibrahim</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>12</td>\n",
       "      <td>2023-06-16</td>\n",
       "      <td>Squamous Cell Carcinoma, RP1</td>\n",
       "      <td>RP1</td>\n",
       "      <td>Evaluate degree of pathologic response at 16 w...</td>\n",
       "      <td>Evaluate the duration of response, Evaluate pr...</td>\n",
       "      <td>Victor - United States</td>\n",
       "      <td>2025-12</td>\n",
       "      <td>2023-05-15</td>\n",
       "      <td>2024-03-26</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>NCT03767348</td>\n",
       "      <td>RP-1</td>\n",
       "      <td>An Open-Label, Multicenter, Phase 1/2 Study of...</td>\n",
       "      <td>Replimune Inc.</td>\n",
       "      <td>IGNYTE</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>340</td>\n",
       "      <td>2017-09-20</td>\n",
       "      <td>Cancer, Melanoma (Skin), Mismatch Repair Defic...</td>\n",
       "      <td>RP1, nivolumab</td>\n",
       "      <td>Percentage of adverse events (AEs), Percentage...</td>\n",
       "      <td>Percentage of biologic activity, Percentage su...</td>\n",
       "      <td>Birmingham - United States, Gilbert - United S...</td>\n",
       "      <td>2024-11</td>\n",
       "      <td>2018-12-06</td>\n",
       "      <td>2023-08-02</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>NCT06395116</td>\n",
       "      <td>RP-1</td>\n",
       "      <td>\"Influence of Fabrication Technique on Microbi...</td>\n",
       "      <td>Menoufia University</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>ACTIVE_NOT_RECRUITING</td>\n",
       "      <td>60</td>\n",
       "      <td>2023-01-20</td>\n",
       "      <td>Inflammatory Response, Microbial Colonization,...</td>\n",
       "      <td>Denture base material</td>\n",
       "      <td>Biofilm formation</td>\n",
       "      <td>No secondary outcomes listed</td>\n",
       "      <td>Mansoura - Egypt</td>\n",
       "      <td>2024-07-04</td>\n",
       "      <td>2024-05-01</td>\n",
       "      <td>2024-05-01</td>\n",
       "      <td>OBSERVATIONAL</td>\n",
       "      <td>Not Available</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>NCT02786381</td>\n",
       "      <td>RP-1</td>\n",
       "      <td>Idylla Respiratory (IFV-RSV) Panel Clinical Te...</td>\n",
       "      <td>Janssen Pharmaceutica N.V., Belgium</td>\n",
       "      <td>RP1</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>213</td>\n",
       "      <td>2015-11</td>\n",
       "      <td>Respiratory Tract Infections, Influenza, Human...</td>\n",
       "      <td>No interventions listed</td>\n",
       "      <td>Product performance as measured by positive an...</td>\n",
       "      <td>No secondary outcomes listed</td>\n",
       "      <td>Pensacola - United States</td>\n",
       "      <td>2016-10</td>\n",
       "      <td>2016-06-01</td>\n",
       "      <td>2016-11-22</td>\n",
       "      <td>OBSERVATIONAL</td>\n",
       "      <td>Not Available</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>NCT06216938</td>\n",
       "      <td>RP-1</td>\n",
       "      <td>Phase I Pilot Study of RP1 in Primary Melanoma...</td>\n",
       "      <td>Yana Najjar</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>25</td>\n",
       "      <td>2024-02-02</td>\n",
       "      <td>Melanoma</td>\n",
       "      <td>Vusolimogene oderparepvec (RP1)</td>\n",
       "      <td>Rate of Sentinel Lymph Node (SLN) Positivity</td>\n",
       "      <td>Incidence of all treatment-emergent adverse ev...</td>\n",
       "      <td>Pittsburgh - United States</td>\n",
       "      <td>2026-01-31</td>\n",
       "      <td>2024-01-22</td>\n",
       "      <td>2024-03-04</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>EARLY_PHASE1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>NCT04349436</td>\n",
       "      <td>RP-1</td>\n",
       "      <td>An Open-Label, Multicenter, Phase 1B/2 Study o...</td>\n",
       "      <td>Replimune Inc.</td>\n",
       "      <td>ARTACUS</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>65</td>\n",
       "      <td>2020-05-15</td>\n",
       "      <td>Cutaneous Squamous Cell Carcinoma, Merkel Cell...</td>\n",
       "      <td>RP1, intra-tumoral injection, oncolytic virus</td>\n",
       "      <td>Primary Safety Outcome Measure, Primary Effica...</td>\n",
       "      <td>Duration of response (DOR) by investigator amo...</td>\n",
       "      <td>Phoenix - United States, La Jolla - United Sta...</td>\n",
       "      <td>2027-09</td>\n",
       "      <td>2020-04-16</td>\n",
       "      <td>2024-03-01</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>NCT04050436</td>\n",
       "      <td>RP-1</td>\n",
       "      <td>A Randomized, Controlled, Open-Label, Phase 2 ...</td>\n",
       "      <td>Replimune Inc.</td>\n",
       "      <td>CERPASS</td>\n",
       "      <td>ACTIVE_NOT_RECRUITING</td>\n",
       "      <td>231</td>\n",
       "      <td>2019-10-08</td>\n",
       "      <td>Cutaneous Squamous Cell Carcinoma, Advanced Cu...</td>\n",
       "      <td>Cemiplimab, RP1</td>\n",
       "      <td>Objective Response Rate (ORR) according to bli...</td>\n",
       "      <td>Progression Free Survival (PFS) by blinded ind...</td>\n",
       "      <td>La Jolla - United States, Los Angeles - United...</td>\n",
       "      <td>2025-09</td>\n",
       "      <td>2019-08-08</td>\n",
       "      <td>2024-04-02</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>NCT04960579</td>\n",
       "      <td>RP-1</td>\n",
       "      <td>Open-Label, Multicenter, Phase 1 Study to Asse...</td>\n",
       "      <td>Poseida Therapeutics, Inc.</td>\n",
       "      <td>MM</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>231</td>\n",
       "      <td>2022-05-05</td>\n",
       "      <td>Multiple Myeloma</td>\n",
       "      <td>P-BCMA-ALLO1 CAR-T cells, Rimiducid</td>\n",
       "      <td>Phase 1 Part 1: Assess the safety and maximum ...</td>\n",
       "      <td>The safety of P-BCMA-ALLO1, The anti-myeloma e...</td>\n",
       "      <td>San Diego - United States, San Francisco - Uni...</td>\n",
       "      <td>2027-12</td>\n",
       "      <td>2021-07-14</td>\n",
       "      <td>2024-06-21</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>NCT03999021</td>\n",
       "      <td>RP-1</td>\n",
       "      <td>A Phase 1 Open-Label Extension Study to Assess...</td>\n",
       "      <td>Johns Hopkins University</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>ACTIVE_NOT_RECRUITING</td>\n",
       "      <td>30</td>\n",
       "      <td>2019-06-24</td>\n",
       "      <td>Retinitis Pigmentosa</td>\n",
       "      <td>NAC effervescent tablets</td>\n",
       "      <td>Blood Pressure (mmHg), Tolerability of N-Acety...</td>\n",
       "      <td>Change in best corrected visual acuity (BCVA),...</td>\n",
       "      <td>Baltimore - United States</td>\n",
       "      <td>2026-08</td>\n",
       "      <td>2019-06-26</td>\n",
       "      <td>2023-10-10</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>NCT03063021</td>\n",
       "      <td>RP-1</td>\n",
       "      <td>A Phase 1 Open Label Dose Ranging Study to Ass...</td>\n",
       "      <td>Johns Hopkins University</td>\n",
       "      <td>FIGHT-RP1</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>30</td>\n",
       "      <td>2017-02-15</td>\n",
       "      <td>Retinitis Pigmentosa</td>\n",
       "      <td>N-Acetyl Cysteine (NAC)</td>\n",
       "      <td>Assessment of safety and tolerability of N-Ace...</td>\n",
       "      <td>Change from baseline aqueous and serum carbony...</td>\n",
       "      <td>Baltimore - United States</td>\n",
       "      <td>2019-02-11</td>\n",
       "      <td>2017-02-24</td>\n",
       "      <td>2022-09-19</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>NCT06067061</td>\n",
       "      <td>RP-1</td>\n",
       "      <td>\"neoBREASTIM\": A Phase 2 Study of Atezolizumab...</td>\n",
       "      <td>Institut Curie</td>\n",
       "      <td>neoBREASTIM</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>51</td>\n",
       "      <td>2024-04-05</td>\n",
       "      <td>Triple Negative Breast Neoplasms</td>\n",
       "      <td>Atezolizumab + RP1</td>\n",
       "      <td>Safety of the combination Atezolizumab plus RP...</td>\n",
       "      <td>Response rate of RCB Score &lt;= 1 at three cycle...</td>\n",
       "      <td>Paris - France</td>\n",
       "      <td>2026-04-05</td>\n",
       "      <td>2023-10-04</td>\n",
       "      <td>2024-05-30</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>NCT04006457</td>\n",
       "      <td>Ritlecitinib</td>\n",
       "      <td>A PHASE 3 OPEN-LABEL, MULTI-CENTER, LONG-TERM ...</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>ALLEGRO-LT</td>\n",
       "      <td>ACTIVE_NOT_RECRUITING</td>\n",
       "      <td>1051</td>\n",
       "      <td>2019-07-18</td>\n",
       "      <td>Alopecia Areata</td>\n",
       "      <td>PF-06651600, Tetanus and diphtheria toxoids an...</td>\n",
       "      <td>Number of subjects reporting treatment-emergen...</td>\n",
       "      <td>Percentage of subjects with an absolute Severi...</td>\n",
       "      <td>Birmingham - United States, Birmingham - Unite...</td>\n",
       "      <td>2024-07-08</td>\n",
       "      <td>2019-07-05</td>\n",
       "      <td>2023-12-22</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>NCT06163326</td>\n",
       "      <td>Ritlecitinib</td>\n",
       "      <td>A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSE-UP TI...</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Tranquillo LTE</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>400</td>\n",
       "      <td>2024-01-19</td>\n",
       "      <td>Vitiligo</td>\n",
       "      <td>Ritlecitinib, Ritlecitinib 100 mg, Placebo</td>\n",
       "      <td>Incidence of treatment-emergent adverse events...</td>\n",
       "      <td>Response based on T-VASI75 at weeks 4, 8, 12, ...</td>\n",
       "      <td>Encinitas - United States, Huntington Beach - ...</td>\n",
       "      <td>2027-01-30</td>\n",
       "      <td>2023-12-08</td>\n",
       "      <td>2024-06-26</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>NCT05879458</td>\n",
       "      <td>Ritlecitinib</td>\n",
       "      <td>A Single-center, Single-arm, Open-label Phase ...</td>\n",
       "      <td>Icahn School of Medicine at Mount Sinai</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>20</td>\n",
       "      <td>2023-05-17</td>\n",
       "      <td>CTCL, Mycosis Fungoides, Sezary Syndrome</td>\n",
       "      <td>Ritlecitinib</td>\n",
       "      <td>Change in Modified Severity Weighted Assessmen...</td>\n",
       "      <td>Change in Modified Severity Weighted Assessmen...</td>\n",
       "      <td>New York - United States</td>\n",
       "      <td>2026-04</td>\n",
       "      <td>2023-05-30</td>\n",
       "      <td>2024-05-07</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32</th>\n",
       "      <td>NCT05128058</td>\n",
       "      <td>Ritlecitinib</td>\n",
       "      <td>AN OPEN LABEL, PHASE 1, TWO-ARM STUDY TO ASSES...</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>16</td>\n",
       "      <td>2021-10-22</td>\n",
       "      <td>Healthy</td>\n",
       "      <td>Ritlecitinib 50 mg, Ritlecitinib 200 mg</td>\n",
       "      <td>Percent Target Occupancy for JAK3, Percent Tar...</td>\n",
       "      <td>Maximum Observed Plasma Concentration (Cmax) o...</td>\n",
       "      <td>New Haven - United States</td>\n",
       "      <td>2022-01-14</td>\n",
       "      <td>2021-11-19</td>\n",
       "      <td>2023-11-13</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33</th>\n",
       "      <td>NCT05743244</td>\n",
       "      <td>Ritlecitinib</td>\n",
       "      <td>A Phase 2 Multi-Center, Randomized, Double-Bli...</td>\n",
       "      <td>National Institute of Diabetes and Digestive a...</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>78</td>\n",
       "      <td>2023-10-19</td>\n",
       "      <td>Diabetes Mellitus, Type 1</td>\n",
       "      <td>Abrocitinib 200 MG Oral Tablet, Ritlecitinib, ...</td>\n",
       "      <td>The area under the stimulated C-peptide curve ...</td>\n",
       "      <td>No secondary outcomes listed</td>\n",
       "      <td>Orange - United States, Palo Alto - United Sta...</td>\n",
       "      <td>2026-06-30</td>\n",
       "      <td>2023-02-24</td>\n",
       "      <td>2024-05-24</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>34</th>\n",
       "      <td>NCT05852340</td>\n",
       "      <td>Ritlecitinib</td>\n",
       "      <td>A PHASE 1, RANDOMIZED, OPEN-LABEL, CROSSOVER S...</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>12</td>\n",
       "      <td>2023-05-09</td>\n",
       "      <td>Healthy Volunteers, Adult, Pharmacokinetics</td>\n",
       "      <td>Ritlecitinib</td>\n",
       "      <td>Maximum plasma concentration (Cmax), Area unde...</td>\n",
       "      <td>Number of participants reporting adverse events</td>\n",
       "      <td>Brussels - Belgium</td>\n",
       "      <td>2023-07-12</td>\n",
       "      <td>2023-05-10</td>\n",
       "      <td>2023-08-02</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>35</th>\n",
       "      <td>NCT04655040</td>\n",
       "      <td>Ritlecitinib</td>\n",
       "      <td>A PHASE 1, 2-PERIOD, FIXED-SEQUENCE, MULTIPLE-...</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>12</td>\n",
       "      <td>2020-12-18</td>\n",
       "      <td>Healthy Participants</td>\n",
       "      <td>Caffeine, Ritlecitinib</td>\n",
       "      <td>Area under the plasma concentration-time profi...</td>\n",
       "      <td>Incidence of treatment-emergent adverse events...</td>\n",
       "      <td>New Haven - United States</td>\n",
       "      <td>2021-03-05</td>\n",
       "      <td>2020-12-04</td>\n",
       "      <td>2021-03-18</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>36</th>\n",
       "      <td>NCT06172348</td>\n",
       "      <td>Ritlecitinib</td>\n",
       "      <td>A PHASE 1, OPEN-LABEL STUDY IN HEALTHY PARTICI...</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>12</td>\n",
       "      <td>2024-02-01</td>\n",
       "      <td>Healthy Volunteers</td>\n",
       "      <td>Ritlecitinib</td>\n",
       "      <td>Maximum plasma concentration (Cmax), Area unde...</td>\n",
       "      <td>Frequency of adverse events, Frequency of abno...</td>\n",
       "      <td>Brussels - Belgium</td>\n",
       "      <td>2024-03-28</td>\n",
       "      <td>2023-12-15</td>\n",
       "      <td>2024-04-04</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>37</th>\n",
       "      <td>NCT05583526</td>\n",
       "      <td>Ritlecitinib</td>\n",
       "      <td>A PHASE 3 RANDOMIZED, DOUBLE-BLIND, 52-WEEK PL...</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Tranquillo</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>600</td>\n",
       "      <td>2022-12-01</td>\n",
       "      <td>Stable Nonsegmental Vitiligo, Active Nonsegmen...</td>\n",
       "      <td>Ritlecitinib, Placebo</td>\n",
       "      <td>US only Co-Primary Endpoints: Response based o...</td>\n",
       "      <td>US-Only: Response based on F-VASI75 at 24, 26 ...</td>\n",
       "      <td>Birmingham - United States, Birmingham - Unite...</td>\n",
       "      <td>2025-07-28</td>\n",
       "      <td>2022-10-17</td>\n",
       "      <td>2024-06-03</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>38</th>\n",
       "      <td>NCT06373458</td>\n",
       "      <td>Ritlecitinib</td>\n",
       "      <td>A Single-Center, Two-Arm, Open-Label Phase IIA...</td>\n",
       "      <td>Icahn School of Medicine at Mount Sinai</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>30</td>\n",
       "      <td>2024-06-30</td>\n",
       "      <td>Keloid</td>\n",
       "      <td>Ritlecitinib</td>\n",
       "      <td>Recurrence Rate, Change in Detroid Keloid Scal...</td>\n",
       "      <td>Change in Peak keloid tension, Change in Detro...</td>\n",
       "      <td>New York - United States</td>\n",
       "      <td>2026-03</td>\n",
       "      <td>2024-04-18</td>\n",
       "      <td>2024-06-04</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>39</th>\n",
       "      <td>NCT05549934</td>\n",
       "      <td>Ritlecitinib</td>\n",
       "      <td>A Pilot Study to Assess Safety and Biomarker R...</td>\n",
       "      <td>Emma Guttman</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>50</td>\n",
       "      <td>2022-12-15</td>\n",
       "      <td>Cicatricial Alopecia</td>\n",
       "      <td>PF-06651600</td>\n",
       "      <td>Number of Treatment-Emergent Adverse Events, S...</td>\n",
       "      <td>Change in Ct values of mRNA levels of CXCR3, C...</td>\n",
       "      <td>New York - United States</td>\n",
       "      <td>2024-12</td>\n",
       "      <td>2022-09-22</td>\n",
       "      <td>2023-08-14</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>40</th>\n",
       "      <td>NCT05097716</td>\n",
       "      <td>Ritlecitinib</td>\n",
       "      <td>PHASE 1, OPEN-LABEL, FIXED-SEQUENCE, 2-PERIOD ...</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>12</td>\n",
       "      <td>2021-11-02</td>\n",
       "      <td>Healthy Volunteers</td>\n",
       "      <td>Ritlecitinib, Tolbutamide</td>\n",
       "      <td>Maximum Plasma Concentration (Cmax) of Tolbuta...</td>\n",
       "      <td>Number of Participants With Treatment-Emergent...</td>\n",
       "      <td>New Haven - United States</td>\n",
       "      <td>2022-01-10</td>\n",
       "      <td>2021-10-28</td>\n",
       "      <td>2023-10-06</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>41</th>\n",
       "      <td>NCT05040295</td>\n",
       "      <td>Ritlecitinib</td>\n",
       "      <td>A PHASE 1, RANDOMIZED, OPEN-LABEL, CROSS-OVER,...</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>12</td>\n",
       "      <td>2021-09-10</td>\n",
       "      <td>Healthy Participants</td>\n",
       "      <td>ritlecitinib, ritlecitinib, ritlecitinib</td>\n",
       "      <td>Area Under the Plasma Concentration-Time Profi...</td>\n",
       "      <td>Number of Participants With Treatment-Emergent...</td>\n",
       "      <td>New Haven - United States</td>\n",
       "      <td>2021-11-19</td>\n",
       "      <td>2021-09-10</td>\n",
       "      <td>2023-08-21</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>42</th>\n",
       "      <td>NCT04413617</td>\n",
       "      <td>Ritlecitinib</td>\n",
       "      <td>A 24-WEEK RANDOMIZED, DOUBLE-BLIND, PARALLEL G...</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>460</td>\n",
       "      <td>2020-07-29</td>\n",
       "      <td>Rheumatoid Arthritis</td>\n",
       "      <td>PF-06650833, PF-06651600, Tofacitinib</td>\n",
       "      <td>Change From Baseline (BL) in Disease Activity ...</td>\n",
       "      <td>DAS28-CRP Remission (&lt;2.6) Rates at Week 24, N...</td>\n",
       "      <td>Pleven - Bulgaria, Plovdiv - Bulgaria, Plovdiv...</td>\n",
       "      <td>2022-02-07</td>\n",
       "      <td>2020-06-04</td>\n",
       "      <td>2023-04-07</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>43</th>\n",
       "      <td>NCT04517864</td>\n",
       "      <td>Ritlecitinib</td>\n",
       "      <td>A PHASE 2a, RANDOMIZED, DOUBLE-BLIND, PLACEBO-...</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Allegro2a</td>\n",
       "      <td>TERMINATED</td>\n",
       "      <td>71</td>\n",
       "      <td>2020-09-15</td>\n",
       "      <td>Alopecia Areata</td>\n",
       "      <td>PF-06651600, Placebo</td>\n",
       "      <td>Change From Baseline in I-V Interwave Latency ...</td>\n",
       "      <td>Change From Baseline in I-V Interwave Latency ...</td>\n",
       "      <td>Huntington Beach - United States, Irvine - Uni...</td>\n",
       "      <td>2022-01-04</td>\n",
       "      <td>2020-08-18</td>\n",
       "      <td>2024-06-18</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>44</th>\n",
       "      <td>NCT05522556</td>\n",
       "      <td>Ritlecitinib</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>AVAILABLE</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>Unknown Date</td>\n",
       "      <td>Alopecia Areata</td>\n",
       "      <td>Ritlecitinib</td>\n",
       "      <td>No primary outcomes listed</td>\n",
       "      <td>No secondary outcomes listed</td>\n",
       "      <td>No locations listed</td>\n",
       "      <td>Unknown Date</td>\n",
       "      <td>2022-08-31</td>\n",
       "      <td>2023-11-13</td>\n",
       "      <td>EXPANDED_ACCESS</td>\n",
       "      <td>Not Available</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>45</th>\n",
       "      <td>NCT03732807</td>\n",
       "      <td>Ritlecitinib</td>\n",
       "      <td>A PHASE 2B/3 RANDOMIZED, DOUBLE-BLIND, PLACEBO...</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>ALLEGRO-2b/3</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>718</td>\n",
       "      <td>2018-12-03</td>\n",
       "      <td>Alopecia Areata</td>\n",
       "      <td>PF-06651600 Induction Dose, PF-06651600 Mainte...</td>\n",
       "      <td>Percentage of Participants With an Absolute Se...</td>\n",
       "      <td>Percentage of Participants With an Absolute SA...</td>\n",
       "      <td>Birmingham - United States, Birmingham - Unite...</td>\n",
       "      <td>2020-12-31</td>\n",
       "      <td>2018-11-07</td>\n",
       "      <td>2022-02-24</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2, PHASE3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>46</th>\n",
       "      <td>NCT06072183</td>\n",
       "      <td>Ritlecitinib</td>\n",
       "      <td>A PHASE 3 RANDOMIZED, DOUBLE-BLIND, 52-WEEK PL...</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Tranquillo 2</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>1450</td>\n",
       "      <td>2023-11-08</td>\n",
       "      <td>Stable Nonsegmental Vitiligo, Active Nonsegmen...</td>\n",
       "      <td>Ritlecitinib, Ritlecitinib, Placebo</td>\n",
       "      <td>US only Co-Primary Endpoints: Response based o...</td>\n",
       "      <td>Response based on F-VASI75 at 24 and 36 weeks,...</td>\n",
       "      <td>Birmingham - United States, Birmingham - Unite...</td>\n",
       "      <td>2027-07-14</td>\n",
       "      <td>2023-10-10</td>\n",
       "      <td>2024-06-26</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>47</th>\n",
       "      <td>NCT05636293</td>\n",
       "      <td>Ritlecitinib</td>\n",
       "      <td>Double Blind, Placebo-controlled Trial to Esta...</td>\n",
       "      <td>Massachusetts General Hospital</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>30</td>\n",
       "      <td>2023-03-01</td>\n",
       "      <td>Celiac Disease</td>\n",
       "      <td>Ritlecitinib, Placebo, Gluten</td>\n",
       "      <td>Change in Small Intestinal Histology based on ...</td>\n",
       "      <td>Serology, Changes in Small Intestinal Histolog...</td>\n",
       "      <td>Boston - United States</td>\n",
       "      <td>2025-08-01</td>\n",
       "      <td>2022-12-05</td>\n",
       "      <td>2024-02-28</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>48</th>\n",
       "      <td>NCT05650333</td>\n",
       "      <td>Ritlecitinib</td>\n",
       "      <td>AN INTERVENTIONAL PK, PD, PHASE 1, OPEN-LABEL ...</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>15</td>\n",
       "      <td>2023-03-02</td>\n",
       "      <td>Alopecia Areata</td>\n",
       "      <td>Ritlecitinib 20 mg</td>\n",
       "      <td>Area under the plasma concentration time profi...</td>\n",
       "      <td>Maximum Observed Plasma Concentration (Cmax), ...</td>\n",
       "      <td>Encinitas - United States, Coral Gables - Unit...</td>\n",
       "      <td>2023-08-11</td>\n",
       "      <td>2022-12-14</td>\n",
       "      <td>2023-08-25</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>49</th>\n",
       "      <td>NCT06369454</td>\n",
       "      <td>Ritlecitinib</td>\n",
       "      <td>A PHASE 1, RANDOMIZED, OPEN-LABEL, 2-SEQUENCE,...</td>\n",
       "      <td>Pfizer</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>ACTIVE_NOT_RECRUITING</td>\n",
       "      <td>6</td>\n",
       "      <td>2024-05-03</td>\n",
       "      <td>Healthy Volunteers</td>\n",
       "      <td>Ritlecitinib</td>\n",
       "      <td>Site of capsule disintegration and MR microsph...</td>\n",
       "      <td>Maximum plasma concentration (Cmax), Area unde...</td>\n",
       "      <td>Lexington - United States</td>\n",
       "      <td>2024-08-02</td>\n",
       "      <td>2024-04-17</td>\n",
       "      <td>2024-06-27</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>50</th>\n",
       "      <td>NCT06450366</td>\n",
       "      <td>MK-0616</td>\n",
       "      <td>A Phase 3, Randomized, Double-Blind Study to E...</td>\n",
       "      <td>Merck Sharp &amp; Dohme LLC</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>NOT_YET_RECRUITING</td>\n",
       "      <td>300</td>\n",
       "      <td>2024-07-15</td>\n",
       "      <td>Hypercholesterolemia</td>\n",
       "      <td>MK-0616, Ezetimibe, Bempedoic Acid, Placebo fo...</td>\n",
       "      <td>Mean Percent Change from Baseline in LDL-C at ...</td>\n",
       "      <td>Mean Percent Change from Baseline in Apolipopr...</td>\n",
       "      <td>No locations listed</td>\n",
       "      <td>2025-07-21</td>\n",
       "      <td>2024-06-10</td>\n",
       "      <td>2024-06-10</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>51</th>\n",
       "      <td>NCT05934292</td>\n",
       "      <td>MK-0616</td>\n",
       "      <td>An Open-Label, Single-Dose Clinical Study to E...</td>\n",
       "      <td>Merck Sharp &amp; Dohme LLC</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>33</td>\n",
       "      <td>2023-07-20</td>\n",
       "      <td>Hypercholesterolaemia</td>\n",
       "      <td>MK-0616</td>\n",
       "      <td>Panels A, B, and D: Area Under the Concentrati...</td>\n",
       "      <td>Dialysate Clearance (CLd) of MK-0616, Dialysat...</td>\n",
       "      <td>Hallandale Beach - United States, Miami - Unit...</td>\n",
       "      <td>2024-01-19</td>\n",
       "      <td>2023-07-06</td>\n",
       "      <td>2024-02-07</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>52</th>\n",
       "      <td>NCT05261126</td>\n",
       "      <td>MK-0616</td>\n",
       "      <td>A Phase 2b, Randomized, Double-Blind, Placebo-...</td>\n",
       "      <td>Merck Sharp &amp; Dohme LLC</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>381</td>\n",
       "      <td>2022-03-10</td>\n",
       "      <td>Hypercholesterolemia, Familial Hypercholestero...</td>\n",
       "      <td>MK-0616, Placebo</td>\n",
       "      <td>Percent Change From Baseline in Low-density Li...</td>\n",
       "      <td>Percent Change From Baseline in Apolipoprotein...</td>\n",
       "      <td>Beverly Hills - United States, Sacramento - Un...</td>\n",
       "      <td>2022-11-28</td>\n",
       "      <td>2022-03-02</td>\n",
       "      <td>2023-12-06</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>53</th>\n",
       "      <td>NCT05070390</td>\n",
       "      <td>MK-0616</td>\n",
       "      <td>An Open-Label Clinical Study to Evaluate the P...</td>\n",
       "      <td>Merck Sharp &amp; Dohme LLC</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>18</td>\n",
       "      <td>2021-11-16</td>\n",
       "      <td>Moderate Renal Impairment</td>\n",
       "      <td>MK-0616</td>\n",
       "      <td>Area Under the Concentration-Time Curve from T...</td>\n",
       "      <td>Number of Participants Experiencing an Adverse...</td>\n",
       "      <td>Hallandale Beach - United States, Knoxville - ...</td>\n",
       "      <td>2023-05-03</td>\n",
       "      <td>2021-10-07</td>\n",
       "      <td>2023-05-23</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>54</th>\n",
       "      <td>NCT05952869</td>\n",
       "      <td>MK-0616</td>\n",
       "      <td>A Phase 3, Randomized, Double-Blind, Placebo-C...</td>\n",
       "      <td>Merck Sharp &amp; Dohme LLC</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>ACTIVE_NOT_RECRUITING</td>\n",
       "      <td>270</td>\n",
       "      <td>2023-08-08</td>\n",
       "      <td>Hypercholesterolemia, Familial Hypercholestero...</td>\n",
       "      <td>MK-0616, Placebo</td>\n",
       "      <td>Mean percent change from baseline in low-densi...</td>\n",
       "      <td>Mean percent change from baseline in LDL-C at ...</td>\n",
       "      <td>Daphne - United States, Boca Raton - United St...</td>\n",
       "      <td>2025-04-28</td>\n",
       "      <td>2023-07-19</td>\n",
       "      <td>2024-03-13</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>55</th>\n",
       "      <td>NCT05952856</td>\n",
       "      <td>MK-0616</td>\n",
       "      <td>A Phase 3, Randomized, Double-Blind, Placebo-C...</td>\n",
       "      <td>Merck Sharp &amp; Dohme LLC</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>ACTIVE_NOT_RECRUITING</td>\n",
       "      <td>2760</td>\n",
       "      <td>2023-08-10</td>\n",
       "      <td>Hypercholesterolemia, Familial Hypercholestero...</td>\n",
       "      <td>MK-0616, Placebo</td>\n",
       "      <td>Mean percent change from baseline in low-densi...</td>\n",
       "      <td>Mean percent change from baseline in LDL-C at ...</td>\n",
       "      <td>Daphne - United States, Foley - United States,...</td>\n",
       "      <td>2025-09-15</td>\n",
       "      <td>2023-07-19</td>\n",
       "      <td>2024-05-17</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>56</th>\n",
       "      <td>NCT06008756</td>\n",
       "      <td>MK-0616</td>\n",
       "      <td>Phase 3 Randomized, Placebo-Controlled Clinica...</td>\n",
       "      <td>Merck Sharp &amp; Dohme LLC</td>\n",
       "      <td>Unknown</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>14550</td>\n",
       "      <td>2023-10-09</td>\n",
       "      <td>Arteriosclerosis, Hypercholesterolaemia</td>\n",
       "      <td>MK-0616, Placebo</td>\n",
       "      <td>Time to First Occurrence of Coronary Heart Dis...</td>\n",
       "      <td>Time to First Occurrence of 3-point MACE, Time...</td>\n",
       "      <td>Alexander City - United States, Birmingham - U...</td>\n",
       "      <td>2029-11-29</td>\n",
       "      <td>2023-08-24</td>\n",
       "      <td>2024-06-21</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE3</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "         NCT ID         Asset  \\\n",
       "0   NCT01636492    Bitopertin   \n",
       "1   NCT05308472    Bitopertin   \n",
       "2   NCT01192880    Bitopertin   \n",
       "3   NCT05883748    Bitopertin   \n",
       "4   NCT02019290    Bitopertin   \n",
       "5   NCT05828108    Bitopertin   \n",
       "6   NCT03271541    Bitopertin   \n",
       "7   NCT01192906    Bitopertin   \n",
       "8   NCT01234779    Bitopertin   \n",
       "9   NCT01235559    Bitopertin   \n",
       "10  NCT01235585    Bitopertin   \n",
       "11  NCT01674361    Bitopertin   \n",
       "12  NCT06139055     GSBR-1290   \n",
       "13  NCT05893043     GSBR-1290   \n",
       "14  NCT05762471     GSBR-1290   \n",
       "15  NCT02709876          RP-1   \n",
       "16  NCT04776889          RP-1   \n",
       "17  NCT06264180          RP-1   \n",
       "18  NCT05858229          RP-1   \n",
       "19  NCT03767348          RP-1   \n",
       "20  NCT06395116          RP-1   \n",
       "21  NCT02786381          RP-1   \n",
       "22  NCT06216938          RP-1   \n",
       "23  NCT04349436          RP-1   \n",
       "24  NCT04050436          RP-1   \n",
       "25  NCT04960579          RP-1   \n",
       "26  NCT03999021          RP-1   \n",
       "27  NCT03063021          RP-1   \n",
       "28  NCT06067061          RP-1   \n",
       "29  NCT04006457  Ritlecitinib   \n",
       "30  NCT06163326  Ritlecitinib   \n",
       "31  NCT05879458  Ritlecitinib   \n",
       "32  NCT05128058  Ritlecitinib   \n",
       "33  NCT05743244  Ritlecitinib   \n",
       "34  NCT05852340  Ritlecitinib   \n",
       "35  NCT04655040  Ritlecitinib   \n",
       "36  NCT06172348  Ritlecitinib   \n",
       "37  NCT05583526  Ritlecitinib   \n",
       "38  NCT06373458  Ritlecitinib   \n",
       "39  NCT05549934  Ritlecitinib   \n",
       "40  NCT05097716  Ritlecitinib   \n",
       "41  NCT05040295  Ritlecitinib   \n",
       "42  NCT04413617  Ritlecitinib   \n",
       "43  NCT04517864  Ritlecitinib   \n",
       "44  NCT05522556  Ritlecitinib   \n",
       "45  NCT03732807  Ritlecitinib   \n",
       "46  NCT06072183  Ritlecitinib   \n",
       "47  NCT05636293  Ritlecitinib   \n",
       "48  NCT05650333  Ritlecitinib   \n",
       "49  NCT06369454  Ritlecitinib   \n",
       "50  NCT06450366       MK-0616   \n",
       "51  NCT05934292       MK-0616   \n",
       "52  NCT05261126       MK-0616   \n",
       "53  NCT05070390       MK-0616   \n",
       "54  NCT05952869       MK-0616   \n",
       "55  NCT05952856       MK-0616   \n",
       "56  NCT06008756       MK-0616   \n",
       "\n",
       "                                                Title  \\\n",
       "0   Single Oral Ascending Dose Study of Safety, To...   \n",
       "1   (AURORA) A Randomized, Double-blind, Placebo-C...   \n",
       "2   A Phase III, Multi-Center, Randomized, 24 Week...   \n",
       "3   An Open-Label, Long-Term Study to Investigate ...   \n",
       "4   A SINGLE CENTER, OPEN LABEL, FIXED SEQUENCE ST...   \n",
       "5   A Phase I/II, Intra-Patient Dose-Escalation St...   \n",
       "6   A Phase II, Single Arm, Multicenter, Proof-of-...   \n",
       "7   A Phase III, Multi-center, Randomized, 24 Week...   \n",
       "8   A Phase II, Multi-center, Randomized, 4-week, ...   \n",
       "9   Phase III, Multi-center, Randomized, 12-week, ...   \n",
       "10  Phase III, Multi-center, Randomized, 12-week, ...   \n",
       "11  A Phase II, Multicenter, Randomized, Double-Bl...   \n",
       "12  A 2-part, Phase 1, Randomized Study to Evaluat...   \n",
       "13  A Phase 1, Randomized, Double-blind, Placebo-c...   \n",
       "14  A Phase 1b/2a, Randomized, Double-blind, Place...   \n",
       "15                                            Unknown   \n",
       "16  The Prognosis of Lipid Reprogramming With the ...   \n",
       "17  Randomized, Ph3 Clinical Study Comparing Vusol...   \n",
       "18  A Phase 1B Study of Intralesional Injection of...   \n",
       "19  An Open-Label, Multicenter, Phase 1/2 Study of...   \n",
       "20  \"Influence of Fabrication Technique on Microbi...   \n",
       "21  Idylla Respiratory (IFV-RSV) Panel Clinical Te...   \n",
       "22  Phase I Pilot Study of RP1 in Primary Melanoma...   \n",
       "23  An Open-Label, Multicenter, Phase 1B/2 Study o...   \n",
       "24  A Randomized, Controlled, Open-Label, Phase 2 ...   \n",
       "25  Open-Label, Multicenter, Phase 1 Study to Asse...   \n",
       "26  A Phase 1 Open-Label Extension Study to Assess...   \n",
       "27  A Phase 1 Open Label Dose Ranging Study to Ass...   \n",
       "28  \"neoBREASTIM\": A Phase 2 Study of Atezolizumab...   \n",
       "29  A PHASE 3 OPEN-LABEL, MULTI-CENTER, LONG-TERM ...   \n",
       "30  A PHASE 3 RANDOMIZED WITHDRAWAL AND DOSE-UP TI...   \n",
       "31  A Single-center, Single-arm, Open-label Phase ...   \n",
       "32  AN OPEN LABEL, PHASE 1, TWO-ARM STUDY TO ASSES...   \n",
       "33  A Phase 2 Multi-Center, Randomized, Double-Bli...   \n",
       "34  A PHASE 1, RANDOMIZED, OPEN-LABEL, CROSSOVER S...   \n",
       "35  A PHASE 1, 2-PERIOD, FIXED-SEQUENCE, MULTIPLE-...   \n",
       "36  A PHASE 1, OPEN-LABEL STUDY IN HEALTHY PARTICI...   \n",
       "37  A PHASE 3 RANDOMIZED, DOUBLE-BLIND, 52-WEEK PL...   \n",
       "38  A Single-Center, Two-Arm, Open-Label Phase IIA...   \n",
       "39  A Pilot Study to Assess Safety and Biomarker R...   \n",
       "40  PHASE 1, OPEN-LABEL, FIXED-SEQUENCE, 2-PERIOD ...   \n",
       "41  A PHASE 1, RANDOMIZED, OPEN-LABEL, CROSS-OVER,...   \n",
       "42  A 24-WEEK RANDOMIZED, DOUBLE-BLIND, PARALLEL G...   \n",
       "43  A PHASE 2a, RANDOMIZED, DOUBLE-BLIND, PLACEBO-...   \n",
       "44                                            Unknown   \n",
       "45  A PHASE 2B/3 RANDOMIZED, DOUBLE-BLIND, PLACEBO...   \n",
       "46  A PHASE 3 RANDOMIZED, DOUBLE-BLIND, 52-WEEK PL...   \n",
       "47  Double Blind, Placebo-controlled Trial to Esta...   \n",
       "48  AN INTERVENTIONAL PK, PD, PHASE 1, OPEN-LABEL ...   \n",
       "49  A PHASE 1, RANDOMIZED, OPEN-LABEL, 2-SEQUENCE,...   \n",
       "50  A Phase 3, Randomized, Double-Blind Study to E...   \n",
       "51  An Open-Label, Single-Dose Clinical Study to E...   \n",
       "52  A Phase 2b, Randomized, Double-Blind, Placebo-...   \n",
       "53  An Open-Label Clinical Study to Evaluate the P...   \n",
       "54  A Phase 3, Randomized, Double-Blind, Placebo-C...   \n",
       "55  A Phase 3, Randomized, Double-Blind, Placebo-C...   \n",
       "56  Phase 3 Randomized, Placebo-Controlled Clinica...   \n",
       "\n",
       "                                         Lead Sponsor         Acronym  \\\n",
       "0                                   Hoffmann-La Roche         Unknown   \n",
       "1                                  Disc Medicine, Inc         Unknown   \n",
       "2                                   Hoffmann-La Roche         Unknown   \n",
       "3                                  Disc Medicine, Inc         Unknown   \n",
       "4                                   Hoffmann-La Roche         Unknown   \n",
       "5   National Heart, Lung, and Blood Institute (NHLBI)         Unknown   \n",
       "6                                   Hoffmann-La Roche         Unknown   \n",
       "7                                   Hoffmann-La Roche         Unknown   \n",
       "8                                   Hoffmann-La Roche         Unknown   \n",
       "9                                   Hoffmann-La Roche         Unknown   \n",
       "10                                  Hoffmann-La Roche         Unknown   \n",
       "11                                  Hoffmann-La Roche         Unknown   \n",
       "12                                Gasherbrum Bio, Inc         Unknown   \n",
       "13                                Gasherbrum Bio, Inc         Unknown   \n",
       "14                                Gasherbrum Bio, Inc         Unknown   \n",
       "15                                  Stem Cells Arabia         Unknown   \n",
       "16                   National Cancer Institute, Egypt         Unknown   \n",
       "17                                     Replimune Inc.         Unknown   \n",
       "18                                    Sherrif Ibrahim         Unknown   \n",
       "19                                     Replimune Inc.          IGNYTE   \n",
       "20                                Menoufia University         Unknown   \n",
       "21                Janssen Pharmaceutica N.V., Belgium             RP1   \n",
       "22                                        Yana Najjar         Unknown   \n",
       "23                                     Replimune Inc.         ARTACUS   \n",
       "24                                     Replimune Inc.         CERPASS   \n",
       "25                         Poseida Therapeutics, Inc.              MM   \n",
       "26                           Johns Hopkins University         Unknown   \n",
       "27                           Johns Hopkins University       FIGHT-RP1   \n",
       "28                                     Institut Curie     neoBREASTIM   \n",
       "29                                             Pfizer      ALLEGRO-LT   \n",
       "30                                             Pfizer  Tranquillo LTE   \n",
       "31            Icahn School of Medicine at Mount Sinai         Unknown   \n",
       "32                                             Pfizer         Unknown   \n",
       "33  National Institute of Diabetes and Digestive a...         Unknown   \n",
       "34                                             Pfizer         Unknown   \n",
       "35                                             Pfizer         Unknown   \n",
       "36                                             Pfizer         Unknown   \n",
       "37                                             Pfizer      Tranquillo   \n",
       "38            Icahn School of Medicine at Mount Sinai         Unknown   \n",
       "39                                       Emma Guttman         Unknown   \n",
       "40                                             Pfizer         Unknown   \n",
       "41                                             Pfizer         Unknown   \n",
       "42                                             Pfizer         Unknown   \n",
       "43                                             Pfizer       Allegro2a   \n",
       "44                                             Pfizer         Unknown   \n",
       "45                                             Pfizer    ALLEGRO-2b/3   \n",
       "46                                             Pfizer    Tranquillo 2   \n",
       "47                     Massachusetts General Hospital         Unknown   \n",
       "48                                             Pfizer         Unknown   \n",
       "49                                             Pfizer         Unknown   \n",
       "50                            Merck Sharp & Dohme LLC         Unknown   \n",
       "51                            Merck Sharp & Dohme LLC         Unknown   \n",
       "52                            Merck Sharp & Dohme LLC         Unknown   \n",
       "53                            Merck Sharp & Dohme LLC         Unknown   \n",
       "54                            Merck Sharp & Dohme LLC         Unknown   \n",
       "55                            Merck Sharp & Dohme LLC         Unknown   \n",
       "56                            Merck Sharp & Dohme LLC         Unknown   \n",
       "\n",
       "             Overall Status Enrollment    Start Date  \\\n",
       "0                 COMPLETED         71       2005-11   \n",
       "1     ACTIVE_NOT_RECRUITING         75    2022-10-31   \n",
       "2                 COMPLETED        625       2010-11   \n",
       "3   ENROLLING_BY_INVITATION        200    2023-08-31   \n",
       "4                 WITHDRAWN          0    2014-02-10   \n",
       "5                RECRUITING         30    2023-07-25   \n",
       "6                 COMPLETED         12    2017-10-26   \n",
       "7                 COMPLETED        624       2010-12   \n",
       "8                 COMPLETED        301       2011-02   \n",
       "9                 COMPLETED        604       2010-12   \n",
       "10                COMPLETED        597       2010-12   \n",
       "11                COMPLETED         99    2012-12-31   \n",
       "12    ACTIVE_NOT_RECRUITING         70    2023-10-02   \n",
       "13                COMPLETED         18    2023-04-24   \n",
       "14                COMPLETED        142    2023-01-09   \n",
       "15                  UNKNOWN         50       2014-04   \n",
       "16                COMPLETED         70    2019-01-15   \n",
       "17       NOT_YET_RECRUITING        400    2024-06-01   \n",
       "18               RECRUITING         12    2023-06-16   \n",
       "19               RECRUITING        340    2017-09-20   \n",
       "20    ACTIVE_NOT_RECRUITING         60    2023-01-20   \n",
       "21                COMPLETED        213       2015-11   \n",
       "22               RECRUITING         25    2024-02-02   \n",
       "23               RECRUITING         65    2020-05-15   \n",
       "24    ACTIVE_NOT_RECRUITING        231    2019-10-08   \n",
       "25               RECRUITING        231    2022-05-05   \n",
       "26    ACTIVE_NOT_RECRUITING         30    2019-06-24   \n",
       "27                COMPLETED         30    2017-02-15   \n",
       "28               RECRUITING         51    2024-04-05   \n",
       "29    ACTIVE_NOT_RECRUITING       1051    2019-07-18   \n",
       "30               RECRUITING        400    2024-01-19   \n",
       "31               RECRUITING         20    2023-05-17   \n",
       "32                COMPLETED         16    2021-10-22   \n",
       "33               RECRUITING         78    2023-10-19   \n",
       "34                COMPLETED         12    2023-05-09   \n",
       "35                COMPLETED         12    2020-12-18   \n",
       "36                COMPLETED         12    2024-02-01   \n",
       "37               RECRUITING        600    2022-12-01   \n",
       "38               RECRUITING         30    2024-06-30   \n",
       "39               RECRUITING         50    2022-12-15   \n",
       "40                COMPLETED         12    2021-11-02   \n",
       "41                COMPLETED         12    2021-09-10   \n",
       "42                COMPLETED        460    2020-07-29   \n",
       "43               TERMINATED         71    2020-09-15   \n",
       "44                AVAILABLE    Unknown  Unknown Date   \n",
       "45                COMPLETED        718    2018-12-03   \n",
       "46               RECRUITING       1450    2023-11-08   \n",
       "47               RECRUITING         30    2023-03-01   \n",
       "48                COMPLETED         15    2023-03-02   \n",
       "49    ACTIVE_NOT_RECRUITING          6    2024-05-03   \n",
       "50       NOT_YET_RECRUITING        300    2024-07-15   \n",
       "51                COMPLETED         33    2023-07-20   \n",
       "52                COMPLETED        381    2022-03-10   \n",
       "53                COMPLETED         18    2021-11-16   \n",
       "54    ACTIVE_NOT_RECRUITING        270    2023-08-08   \n",
       "55    ACTIVE_NOT_RECRUITING       2760    2023-08-10   \n",
       "56               RECRUITING      14550    2023-10-09   \n",
       "\n",
       "                                           Conditions  \\\n",
       "0                                   Healthy Volunteer   \n",
       "1                       Erythropoietic Protoporphyria   \n",
       "2                                       Schizophrenia   \n",
       "3                       Erythropoietic Protoporphyria   \n",
       "4                                   Healthy Volunteer   \n",
       "5    Steroid-refractory Diamond-Blackfan Anemia (DBA)   \n",
       "6                                    Beta-Thalassemia   \n",
       "7                                       Schizophrenia   \n",
       "8                                       Schizophrenia   \n",
       "9                                       Schizophrenia   \n",
       "10                                      Schizophrenia   \n",
       "11                      Obsessive-Compulsive Disorder   \n",
       "12                                 Healthy Volunteers   \n",
       "13                                 Healthy Volunteers   \n",
       "14     Overweight or Obesity, Type2 Diabetes Mellitus   \n",
       "15                               Retinitis Pigmentosa   \n",
       "16                         Prostate Cancer Metastatic   \n",
       "17                                  Advanced Melanoma   \n",
       "18                       Squamous Cell Carcinoma, RP1   \n",
       "19  Cancer, Melanoma (Skin), Mismatch Repair Defic...   \n",
       "20  Inflammatory Response, Microbial Colonization,...   \n",
       "21  Respiratory Tract Infections, Influenza, Human...   \n",
       "22                                           Melanoma   \n",
       "23  Cutaneous Squamous Cell Carcinoma, Merkel Cell...   \n",
       "24  Cutaneous Squamous Cell Carcinoma, Advanced Cu...   \n",
       "25                                   Multiple Myeloma   \n",
       "26                               Retinitis Pigmentosa   \n",
       "27                               Retinitis Pigmentosa   \n",
       "28                   Triple Negative Breast Neoplasms   \n",
       "29                                    Alopecia Areata   \n",
       "30                                           Vitiligo   \n",
       "31           CTCL, Mycosis Fungoides, Sezary Syndrome   \n",
       "32                                            Healthy   \n",
       "33                          Diabetes Mellitus, Type 1   \n",
       "34        Healthy Volunteers, Adult, Pharmacokinetics   \n",
       "35                               Healthy Participants   \n",
       "36                                 Healthy Volunteers   \n",
       "37  Stable Nonsegmental Vitiligo, Active Nonsegmen...   \n",
       "38                                             Keloid   \n",
       "39                               Cicatricial Alopecia   \n",
       "40                                 Healthy Volunteers   \n",
       "41                               Healthy Participants   \n",
       "42                               Rheumatoid Arthritis   \n",
       "43                                    Alopecia Areata   \n",
       "44                                    Alopecia Areata   \n",
       "45                                    Alopecia Areata   \n",
       "46  Stable Nonsegmental Vitiligo, Active Nonsegmen...   \n",
       "47                                     Celiac Disease   \n",
       "48                                    Alopecia Areata   \n",
       "49                                 Healthy Volunteers   \n",
       "50                               Hypercholesterolemia   \n",
       "51                              Hypercholesterolaemia   \n",
       "52  Hypercholesterolemia, Familial Hypercholestero...   \n",
       "53                          Moderate Renal Impairment   \n",
       "54  Hypercholesterolemia, Familial Hypercholestero...   \n",
       "55  Hypercholesterolemia, Familial Hypercholestero...   \n",
       "56            Arteriosclerosis, Hypercholesterolaemia   \n",
       "\n",
       "                                        Interventions  \\\n",
       "0                                 bitopertin, placebo   \n",
       "1            DISC-1459, DISC-1459, Placebo, DISC-1459   \n",
       "2                 Placebo, Bitopertin, Antipsychotics   \n",
       "3                                DISC-1459, DISC-1459   \n",
       "4                               Midazolam, bitopertin   \n",
       "5                                          Bitopertin   \n",
       "6                                          Bitopertin   \n",
       "7   Placebo, bitopertin [RO4917838], bitopertin [R...   \n",
       "8   bitopertin [RO4917838], bitopertin [RO4917838]...   \n",
       "9   Placebo, bitopertin [RO4917838] level 1, bitop...   \n",
       "10  Placebo, bitopertin [RO4917838], bitopertin [R...   \n",
       "11                          Bitopertin, Placebo, SSRI   \n",
       "12  GSBR-1290 (Capsule/Tablet), GSBR-1290, Placebo...   \n",
       "13                                 GSBR-1290, Placebo   \n",
       "14                                 GSBR-1290, Placebo   \n",
       "15                          Stem Cell Transplantation   \n",
       "16             Rosuvastatin 20mg, surgical castration   \n",
       "17  Vusolimogene Oderparepvec, Nivolumab, Nivoluma...   \n",
       "18                                                RP1   \n",
       "19                                     RP1, nivolumab   \n",
       "20                              Denture base material   \n",
       "21                            No interventions listed   \n",
       "22                    Vusolimogene oderparepvec (RP1)   \n",
       "23      RP1, intra-tumoral injection, oncolytic virus   \n",
       "24                                    Cemiplimab, RP1   \n",
       "25                P-BCMA-ALLO1 CAR-T cells, Rimiducid   \n",
       "26                           NAC effervescent tablets   \n",
       "27                            N-Acetyl Cysteine (NAC)   \n",
       "28                                 Atezolizumab + RP1   \n",
       "29  PF-06651600, Tetanus and diphtheria toxoids an...   \n",
       "30         Ritlecitinib, Ritlecitinib 100 mg, Placebo   \n",
       "31                                       Ritlecitinib   \n",
       "32            Ritlecitinib 50 mg, Ritlecitinib 200 mg   \n",
       "33  Abrocitinib 200 MG Oral Tablet, Ritlecitinib, ...   \n",
       "34                                       Ritlecitinib   \n",
       "35                             Caffeine, Ritlecitinib   \n",
       "36                                       Ritlecitinib   \n",
       "37                              Ritlecitinib, Placebo   \n",
       "38                                       Ritlecitinib   \n",
       "39                                        PF-06651600   \n",
       "40                          Ritlecitinib, Tolbutamide   \n",
       "41           ritlecitinib, ritlecitinib, ritlecitinib   \n",
       "42              PF-06650833, PF-06651600, Tofacitinib   \n",
       "43                               PF-06651600, Placebo   \n",
       "44                                       Ritlecitinib   \n",
       "45  PF-06651600 Induction Dose, PF-06651600 Mainte...   \n",
       "46                Ritlecitinib, Ritlecitinib, Placebo   \n",
       "47                      Ritlecitinib, Placebo, Gluten   \n",
       "48                                 Ritlecitinib 20 mg   \n",
       "49                                       Ritlecitinib   \n",
       "50  MK-0616, Ezetimibe, Bempedoic Acid, Placebo fo...   \n",
       "51                                            MK-0616   \n",
       "52                                   MK-0616, Placebo   \n",
       "53                                            MK-0616   \n",
       "54                                   MK-0616, Placebo   \n",
       "55                                   MK-0616, Placebo   \n",
       "56                                   MK-0616, Placebo   \n",
       "\n",
       "                                   Primary Outcome(s)  \\\n",
       "0                 Safety: Incidence of adverse events   \n",
       "1   Percent change from baseline in whole blood me...   \n",
       "2   Mean Change From Baseline in the Positive and ...   \n",
       "3   Incidence of treatment-emergent adverse events...   \n",
       "4   Change in plasma area under the concentration-...   \n",
       "5                                    Rate of response   \n",
       "6   Safety Outcome: Percentage of Participants wit...   \n",
       "7   Efficacy (PANSS negative symptoms factor score...   \n",
       "8   Change in Positive and Negative Syndrome Scale...   \n",
       "9   Positive symptoms factor score assessed by Pos...   \n",
       "10  Positive symptoms factor score assessed by Pos...   \n",
       "11  Change From Baseline in Total Score on Yale-Br...   \n",
       "12  Part 1: Analysis of Maximum Observed Plasma Co...   \n",
       "13  Number of Participants With Adverse Events (AE...   \n",
       "14  Incidence, severity and relationship of AE/SAE...   \n",
       "15                         ETDRS Visual acuity change   \n",
       "16  Lipid profile, Aggressiveness parameters, Aggr...   \n",
       "17                              Overall Survival (OS)   \n",
       "18  Evaluate degree of pathologic response at 16 w...   \n",
       "19  Percentage of adverse events (AEs), Percentage...   \n",
       "20                                  Biofilm formation   \n",
       "21  Product performance as measured by positive an...   \n",
       "22       Rate of Sentinel Lymph Node (SLN) Positivity   \n",
       "23  Primary Safety Outcome Measure, Primary Effica...   \n",
       "24  Objective Response Rate (ORR) according to bli...   \n",
       "25  Phase 1 Part 1: Assess the safety and maximum ...   \n",
       "26  Blood Pressure (mmHg), Tolerability of N-Acety...   \n",
       "27  Assessment of safety and tolerability of N-Ace...   \n",
       "28  Safety of the combination Atezolizumab plus RP...   \n",
       "29  Number of subjects reporting treatment-emergen...   \n",
       "30  Incidence of treatment-emergent adverse events...   \n",
       "31  Change in Modified Severity Weighted Assessmen...   \n",
       "32  Percent Target Occupancy for JAK3, Percent Tar...   \n",
       "33  The area under the stimulated C-peptide curve ...   \n",
       "34  Maximum plasma concentration (Cmax), Area unde...   \n",
       "35  Area under the plasma concentration-time profi...   \n",
       "36  Maximum plasma concentration (Cmax), Area unde...   \n",
       "37  US only Co-Primary Endpoints: Response based o...   \n",
       "38  Recurrence Rate, Change in Detroid Keloid Scal...   \n",
       "39  Number of Treatment-Emergent Adverse Events, S...   \n",
       "40  Maximum Plasma Concentration (Cmax) of Tolbuta...   \n",
       "41  Area Under the Plasma Concentration-Time Profi...   \n",
       "42  Change From Baseline (BL) in Disease Activity ...   \n",
       "43  Change From Baseline in I-V Interwave Latency ...   \n",
       "44                         No primary outcomes listed   \n",
       "45  Percentage of Participants With an Absolute Se...   \n",
       "46  US only Co-Primary Endpoints: Response based o...   \n",
       "47  Change in Small Intestinal Histology based on ...   \n",
       "48  Area under the plasma concentration time profi...   \n",
       "49  Site of capsule disintegration and MR microsph...   \n",
       "50  Mean Percent Change from Baseline in LDL-C at ...   \n",
       "51  Panels A, B, and D: Area Under the Concentrati...   \n",
       "52  Percent Change From Baseline in Low-density Li...   \n",
       "53  Area Under the Concentration-Time Curve from T...   \n",
       "54  Mean percent change from baseline in low-densi...   \n",
       "55  Mean percent change from baseline in low-densi...   \n",
       "56  Time to First Occurrence of Coronary Heart Dis...   \n",
       "\n",
       "                                 Secondary Outcome(s)  \\\n",
       "0   Pharmacokinetics: Area under the concentration...   \n",
       "1   Total hours of sunlight exposure to skin on da...   \n",
       "2   Mean Change from Baseline in the Personal and ...   \n",
       "3   Change from baseline in daily daylight toleran...   \n",
       "4   Change in 1'-hydroxymidazolam plasma AUC after...   \n",
       "5   Rate of relapse, Long-term safety of drug, Tol...   \n",
       "6   Apparent Clearance of Bitopertin, Volume of Di...   \n",
       "7                        No secondary outcomes listed   \n",
       "8   Clinical response, defined as at least 30% or ...   \n",
       "9   Symptom domains of schizophrenia using Positiv...   \n",
       "10  Symptom domains of schizophrenia using Positiv...   \n",
       "11  Change From Baseline in Clinical Global Impres...   \n",
       "12  Part 1: Number of Participants With Adverse Ev...   \n",
       "13  Analysis of Maximum Observed Plasma Concentrat...   \n",
       "14  Analysis of Cmax at specified timepoints predo...   \n",
       "15  Quality of Life: Questionnaire VFQ-25 (Visual ...   \n",
       "16  short-term clinical outcome, short-term clinic...   \n",
       "17  Progression Free Survival (PFS), Objective Res...   \n",
       "18  Evaluate the duration of response, Evaluate pr...   \n",
       "19  Percentage of biologic activity, Percentage su...   \n",
       "20                       No secondary outcomes listed   \n",
       "21                       No secondary outcomes listed   \n",
       "22  Incidence of all treatment-emergent adverse ev...   \n",
       "23  Duration of response (DOR) by investigator amo...   \n",
       "24  Progression Free Survival (PFS) by blinded ind...   \n",
       "25  The safety of P-BCMA-ALLO1, The anti-myeloma e...   \n",
       "26  Change in best corrected visual acuity (BCVA),...   \n",
       "27  Change from baseline aqueous and serum carbony...   \n",
       "28  Response rate of RCB Score <= 1 at three cycle...   \n",
       "29  Percentage of subjects with an absolute Severi...   \n",
       "30  Response based on T-VASI75 at weeks 4, 8, 12, ...   \n",
       "31  Change in Modified Severity Weighted Assessmen...   \n",
       "32  Maximum Observed Plasma Concentration (Cmax) o...   \n",
       "33                       No secondary outcomes listed   \n",
       "34    Number of participants reporting adverse events   \n",
       "35  Incidence of treatment-emergent adverse events...   \n",
       "36  Frequency of adverse events, Frequency of abno...   \n",
       "37  US-Only: Response based on F-VASI75 at 24, 26 ...   \n",
       "38  Change in Peak keloid tension, Change in Detro...   \n",
       "39  Change in Ct values of mRNA levels of CXCR3, C...   \n",
       "40  Number of Participants With Treatment-Emergent...   \n",
       "41  Number of Participants With Treatment-Emergent...   \n",
       "42  DAS28-CRP Remission (<2.6) Rates at Week 24, N...   \n",
       "43  Change From Baseline in I-V Interwave Latency ...   \n",
       "44                       No secondary outcomes listed   \n",
       "45  Percentage of Participants With an Absolute SA...   \n",
       "46  Response based on F-VASI75 at 24 and 36 weeks,...   \n",
       "47  Serology, Changes in Small Intestinal Histolog...   \n",
       "48  Maximum Observed Plasma Concentration (Cmax), ...   \n",
       "49  Maximum plasma concentration (Cmax), Area unde...   \n",
       "50  Mean Percent Change from Baseline in Apolipopr...   \n",
       "51  Dialysate Clearance (CLd) of MK-0616, Dialysat...   \n",
       "52  Percent Change From Baseline in Apolipoprotein...   \n",
       "53  Number of Participants Experiencing an Adverse...   \n",
       "54  Mean percent change from baseline in LDL-C at ...   \n",
       "55  Mean percent change from baseline in LDL-C at ...   \n",
       "56  Time to First Occurrence of 3-point MACE, Time...   \n",
       "\n",
       "                                            Locations Primary Completion Date  \\\n",
       "0                          Christchurch - New Zealand                 2006-08   \n",
       "1   Birmingham - United States, San Francisco - Un...              2024-02-20   \n",
       "2   Costa Mesa - United States, Escondido - United...                 2014-07   \n",
       "3   Birmingham - United States, San Francisco - Un...                 2028-06   \n",
       "4                                 No locations listed              2014-03-31   \n",
       "5                            Bethesda - United States              2029-05-01   \n",
       "6   Genova - Italy, Milano - Italy, Baabda - Leban...              2018-06-29   \n",
       "7   Carson - United States, Oceanside - United Sta...                 2014-07   \n",
       "8   Little Rock - United States, Cerritos - United...                 2012-09   \n",
       "9   Costa Mesa - United States, Escondido - United...                 2015-03   \n",
       "10  Carson - United States, Garden Grove - United ...                 2014-09   \n",
       "11  Oceanside - United States, Stanford - United S...              2015-04-30   \n",
       "12  Miami - United States, Miami - United States, ...                 2024-03   \n",
       "13                            Anaheim - United States              2023-06-28   \n",
       "14  Anaheim - United States, Chula Vista - United ...              2024-04-11   \n",
       "15                                     Amman - Jordan                 2020-09   \n",
       "16                                      Cairo - Egypt              2020-12-30   \n",
       "17                                No locations listed              2029-01-01   \n",
       "18                             Victor - United States                 2025-12   \n",
       "19  Birmingham - United States, Gilbert - United S...                 2024-11   \n",
       "20                                   Mansoura - Egypt              2024-07-04   \n",
       "21                          Pensacola - United States                 2016-10   \n",
       "22                         Pittsburgh - United States              2026-01-31   \n",
       "23  Phoenix - United States, La Jolla - United Sta...                 2027-09   \n",
       "24  La Jolla - United States, Los Angeles - United...                 2025-09   \n",
       "25  San Diego - United States, San Francisco - Uni...                 2027-12   \n",
       "26                          Baltimore - United States                 2026-08   \n",
       "27                          Baltimore - United States              2019-02-11   \n",
       "28                                     Paris - France              2026-04-05   \n",
       "29  Birmingham - United States, Birmingham - Unite...              2024-07-08   \n",
       "30  Encinitas - United States, Huntington Beach - ...              2027-01-30   \n",
       "31                           New York - United States                 2026-04   \n",
       "32                          New Haven - United States              2022-01-14   \n",
       "33  Orange - United States, Palo Alto - United Sta...              2026-06-30   \n",
       "34                                 Brussels - Belgium              2023-07-12   \n",
       "35                          New Haven - United States              2021-03-05   \n",
       "36                                 Brussels - Belgium              2024-03-28   \n",
       "37  Birmingham - United States, Birmingham - Unite...              2025-07-28   \n",
       "38                           New York - United States                 2026-03   \n",
       "39                           New York - United States                 2024-12   \n",
       "40                          New Haven - United States              2022-01-10   \n",
       "41                          New Haven - United States              2021-11-19   \n",
       "42  Pleven - Bulgaria, Plovdiv - Bulgaria, Plovdiv...              2022-02-07   \n",
       "43  Huntington Beach - United States, Irvine - Uni...              2022-01-04   \n",
       "44                                No locations listed            Unknown Date   \n",
       "45  Birmingham - United States, Birmingham - Unite...              2020-12-31   \n",
       "46  Birmingham - United States, Birmingham - Unite...              2027-07-14   \n",
       "47                             Boston - United States              2025-08-01   \n",
       "48  Encinitas - United States, Coral Gables - Unit...              2023-08-11   \n",
       "49                          Lexington - United States              2024-08-02   \n",
       "50                                No locations listed              2025-07-21   \n",
       "51  Hallandale Beach - United States, Miami - Unit...              2024-01-19   \n",
       "52  Beverly Hills - United States, Sacramento - Un...              2022-11-28   \n",
       "53  Hallandale Beach - United States, Knoxville - ...              2023-05-03   \n",
       "54  Daphne - United States, Boca Raton - United St...              2025-04-28   \n",
       "55  Daphne - United States, Foley - United States,...              2025-09-15   \n",
       "56  Alexander City - United States, Birmingham - U...              2029-11-29   \n",
       "\n",
       "   Study First Post Date Last Update Post Date       Study Type  \\\n",
       "0             2012-07-10            2016-11-02   INTERVENTIONAL   \n",
       "1             2022-04-04            2024-04-15   INTERVENTIONAL   \n",
       "2             2010-09-01            2017-02-15   INTERVENTIONAL   \n",
       "3             2023-06-01            2024-02-22   INTERVENTIONAL   \n",
       "4             2013-12-24            2017-10-25   INTERVENTIONAL   \n",
       "5             2023-04-25            2024-04-10   INTERVENTIONAL   \n",
       "6             2017-09-05            2018-10-05   INTERVENTIONAL   \n",
       "7             2010-09-01            2016-11-02   INTERVENTIONAL   \n",
       "8             2010-11-04            2016-11-02   INTERVENTIONAL   \n",
       "9             2010-11-05            2016-11-02   INTERVENTIONAL   \n",
       "10            2010-11-05            2016-11-02   INTERVENTIONAL   \n",
       "11            2012-08-28            2017-08-02   INTERVENTIONAL   \n",
       "12            2023-11-18            2024-02-15   INTERVENTIONAL   \n",
       "13            2023-06-07            2023-07-14   INTERVENTIONAL   \n",
       "14            2023-03-09            2024-04-25   INTERVENTIONAL   \n",
       "15            2016-03-16            2020-03-17   INTERVENTIONAL   \n",
       "16            2021-03-02            2021-03-02   INTERVENTIONAL   \n",
       "17            2024-02-16            2024-02-16   INTERVENTIONAL   \n",
       "18            2023-05-15            2024-03-26   INTERVENTIONAL   \n",
       "19            2018-12-06            2023-08-02   INTERVENTIONAL   \n",
       "20            2024-05-01            2024-05-01    OBSERVATIONAL   \n",
       "21            2016-06-01            2016-11-22    OBSERVATIONAL   \n",
       "22            2024-01-22            2024-03-04   INTERVENTIONAL   \n",
       "23            2020-04-16            2024-03-01   INTERVENTIONAL   \n",
       "24            2019-08-08            2024-04-02   INTERVENTIONAL   \n",
       "25            2021-07-14            2024-06-21   INTERVENTIONAL   \n",
       "26            2019-06-26            2023-10-10   INTERVENTIONAL   \n",
       "27            2017-02-24            2022-09-19   INTERVENTIONAL   \n",
       "28            2023-10-04            2024-05-30   INTERVENTIONAL   \n",
       "29            2019-07-05            2023-12-22   INTERVENTIONAL   \n",
       "30            2023-12-08            2024-06-26   INTERVENTIONAL   \n",
       "31            2023-05-30            2024-05-07   INTERVENTIONAL   \n",
       "32            2021-11-19            2023-11-13   INTERVENTIONAL   \n",
       "33            2023-02-24            2024-05-24   INTERVENTIONAL   \n",
       "34            2023-05-10            2023-08-02   INTERVENTIONAL   \n",
       "35            2020-12-04            2021-03-18   INTERVENTIONAL   \n",
       "36            2023-12-15            2024-04-04   INTERVENTIONAL   \n",
       "37            2022-10-17            2024-06-03   INTERVENTIONAL   \n",
       "38            2024-04-18            2024-06-04   INTERVENTIONAL   \n",
       "39            2022-09-22            2023-08-14   INTERVENTIONAL   \n",
       "40            2021-10-28            2023-10-06   INTERVENTIONAL   \n",
       "41            2021-09-10            2023-08-21   INTERVENTIONAL   \n",
       "42            2020-06-04            2023-04-07   INTERVENTIONAL   \n",
       "43            2020-08-18            2024-06-18   INTERVENTIONAL   \n",
       "44            2022-08-31            2023-11-13  EXPANDED_ACCESS   \n",
       "45            2018-11-07            2022-02-24   INTERVENTIONAL   \n",
       "46            2023-10-10            2024-06-26   INTERVENTIONAL   \n",
       "47            2022-12-05            2024-02-28   INTERVENTIONAL   \n",
       "48            2022-12-14            2023-08-25   INTERVENTIONAL   \n",
       "49            2024-04-17            2024-06-27   INTERVENTIONAL   \n",
       "50            2024-06-10            2024-06-10   INTERVENTIONAL   \n",
       "51            2023-07-06            2024-02-07   INTERVENTIONAL   \n",
       "52            2022-03-02            2023-12-06   INTERVENTIONAL   \n",
       "53            2021-10-07            2023-05-23   INTERVENTIONAL   \n",
       "54            2023-07-19            2024-03-13   INTERVENTIONAL   \n",
       "55            2023-07-19            2024-05-17   INTERVENTIONAL   \n",
       "56            2023-08-24            2024-06-21   INTERVENTIONAL   \n",
       "\n",
       "            Phases  \n",
       "0           PHASE1  \n",
       "1           PHASE2  \n",
       "2           PHASE3  \n",
       "3   PHASE2, PHASE3  \n",
       "4           PHASE1  \n",
       "5   PHASE1, PHASE2  \n",
       "6           PHASE2  \n",
       "7           PHASE3  \n",
       "8           PHASE2  \n",
       "9           PHASE3  \n",
       "10          PHASE3  \n",
       "11          PHASE2  \n",
       "12          PHASE1  \n",
       "13          PHASE1  \n",
       "14  PHASE1, PHASE2  \n",
       "15  PHASE1, PHASE2  \n",
       "16          PHASE4  \n",
       "17          PHASE3  \n",
       "18  PHASE1, PHASE2  \n",
       "19          PHASE2  \n",
       "20   Not Available  \n",
       "21   Not Available  \n",
       "22    EARLY_PHASE1  \n",
       "23  PHASE1, PHASE2  \n",
       "24          PHASE2  \n",
       "25          PHASE1  \n",
       "26          PHASE1  \n",
       "27          PHASE1  \n",
       "28  PHASE1, PHASE2  \n",
       "29          PHASE3  \n",
       "30          PHASE3  \n",
       "31          PHASE2  \n",
       "32          PHASE1  \n",
       "33          PHASE2  \n",
       "34          PHASE1  \n",
       "35          PHASE1  \n",
       "36          PHASE1  \n",
       "37          PHASE3  \n",
       "38          PHASE2  \n",
       "39          PHASE2  \n",
       "40          PHASE1  \n",
       "41          PHASE1  \n",
       "42          PHASE2  \n",
       "43          PHASE2  \n",
       "44   Not Available  \n",
       "45  PHASE2, PHASE3  \n",
       "46          PHASE3  \n",
       "47          PHASE2  \n",
       "48          PHASE1  \n",
       "49          PHASE1  \n",
       "50          PHASE3  \n",
       "51          PHASE1  \n",
       "52          PHASE2  \n",
       "53          PHASE1  \n",
       "54          PHASE3  \n",
       "55          PHASE3  \n",
       "56          PHASE3  "
      ]
     },
     "execution_count": 17,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import requests\n",
    "import pandas as pd\n",
    "import openpyxl\n",
    "\n",
    "# Read in list of assets of interest and convert to list\n",
    "assetFrame = pd.read_excel('assetList.xlsx')\n",
    "assetList = assetFrame['Asset'].tolist()\n",
    "\n",
    "# Initialize an empty list to store the data\n",
    "data_list = []\n",
    "\n",
    "for asset in assetList:\n",
    "\n",
    "    # Initial URL for the first API call\n",
    "    base_url = \"https://clinicaltrials.gov/api/v2/studies\"\n",
    "    params = {\n",
    "        \"query.term\": asset,\n",
    "        \"pageSize\": 100\n",
    "    }\n",
    "    # Assign asset name from parameter\n",
    "    assetName = params['query.term']\n",
    "\n",
    "    # Loop until there is no nextPageToken\n",
    "    while True:\n",
    "        # Print the current URL (for debugging purposes); Access by looping parameters\n",
    "        print(\"Fetching data from:\", base_url + '?' + '&'.join([f\"{k}={v}\" for k, v in params.items()]))\n",
    "        \n",
    "        # Send a GET request to the API\n",
    "        response = requests.get(base_url, params=params)\n",
    "\n",
    "        # Check if the request was successful\n",
    "        if response.status_code == 200:\n",
    "            data = response.json()  # Parse JSON response\n",
    "            studies = data.get('studies', [])  # Extract the list of studies, pass empty parameters\n",
    "\n",
    "            # Loop through each study and extract specific information\n",
    "            for study in studies:\n",
    "                # Safely access nested keys, Indicates Unknown if unavailable \n",
    "                nctId = study['protocolSection']['identificationModule'].get('nctId', 'Unknown')\n",
    "                studyTitle = study['protocolSection']['identificationModule'].get('officialTitle', 'Unknown')\n",
    "                sponsor = study['protocolSection']['sponsorCollaboratorsModule'].get('leadSponsor', {}).get('name', 'Unknonw Lead Sponsor')\n",
    "                overallStatus = study['protocolSection']['statusModule'].get('overallStatus', 'Unknown')\n",
    "                enrollment = study['protocolSection']['designModule'].get('enrollmentInfo',{}).get('count', 'Unknown')\n",
    "                startDate = study['protocolSection']['statusModule'].get('startDateStruct', {}).get('date', 'Unknown Date')\n",
    "                conditions = ', '.join(study['protocolSection']['conditionsModule'].get('conditions', ['No conditions listed']))\n",
    "                acronym = study['protocolSection']['identificationModule'].get('acronym', 'Unknown')\n",
    "\n",
    "                # Extract interventions safely\n",
    "                interventions_list = study['protocolSection'].get('armsInterventionsModule', {}).get('interventions', [])\n",
    "                interventions = ', '.join([intervention.get('name', 'No intervention name listed') for intervention in interventions_list]) if interventions_list else \"No interventions listed\"\n",
    "\n",
    "                # Extract outcomes safely\n",
    "                primaryOutcomes_list = study['protocolSection'].get('outcomesModule', {}).get('primaryOutcomes', [])\n",
    "                primaryOutcomes = ', '.join([measure.get('measure', 'No primary outcome indicated') for measure in primaryOutcomes_list]) if primaryOutcomes_list else \"No primary outcomes listed\"\n",
    "                secondaryOutcomes_list = study['protocolSection'].get('outcomesModule', {}).get('secondaryOutcomes', [])\n",
    "                secondaryOutcomes = ', '.join([measure.get('measure', 'No secomdary outcomes indicated') for measure in secondaryOutcomes_list]) if secondaryOutcomes_list else \"No secondary outcomes listed\"\n",
    "                \n",
    "                # Extract locations safely\n",
    "                locations_list = study['protocolSection'].get('contactsLocationsModule', {}).get('locations', [])\n",
    "                locations = ', '.join([f\"{location.get('city', 'No City')} - {location.get('country', 'No Country')}\" for location in locations_list]) if locations_list else \"No locations listed\"\n",
    "                \n",
    "                # Extract dates and phases\n",
    "                primaryCompletionDate = study['protocolSection']['statusModule'].get('primaryCompletionDateStruct', {}).get('date', 'Unknown Date')\n",
    "                studyFirstPostDate = study['protocolSection']['statusModule'].get('studyFirstPostDateStruct', {}).get('date', 'Unknown Date')\n",
    "                lastUpdatePostDate = study['protocolSection']['statusModule'].get('lastUpdatePostDateStruct', {}).get('date', 'Unknown Date')\n",
    "                studyType = study['protocolSection']['designModule'].get('studyType', 'Unknown')\n",
    "                phases = ', '.join(study['protocolSection']['designModule'].get('phases', ['Not Available']))\n",
    "\n",
    "                # Append the data to the list as a dictionary\n",
    "                data_list.append({\n",
    "                    \"NCT ID\": nctId,\n",
    "                    \"Asset\": assetName,\n",
    "                    \"Title\": studyTitle,\n",
    "                    \"Lead Sponsor\": sponsor,\n",
    "                    \"Acronym\": acronym,\n",
    "                    \"Overall Status\": overallStatus,\n",
    "                    \"Enrollment\": enrollment,\n",
    "                    \"Start Date\": startDate,\n",
    "                    \"Conditions\": conditions,\n",
    "                    \"Interventions\": interventions,\n",
    "                    \"Primary Outcome(s)\": primaryOutcomes,\n",
    "                    \"Secondary Outcome(s)\": secondaryOutcomes,\n",
    "                    \"Locations\": locations,\n",
    "                    \"Primary Completion Date\": primaryCompletionDate,\n",
    "                    \"Study First Post Date\": studyFirstPostDate,\n",
    "                    \"Last Update Post Date\": lastUpdatePostDate,\n",
    "                    \"Study Type\": studyType,\n",
    "                    \"Phases\": phases\n",
    "                })\n",
    "\n",
    "            # Check for nextPageToken and update the params or break the loop\n",
    "            nextPageToken = data.get('nextPageToken')\n",
    "            if nextPageToken:\n",
    "                params['pageToken'] = nextPageToken  # Set the pageToken for the next request\n",
    "            else:\n",
    "                break  # Exit the loop if no nextPageToken is present\n",
    "        else:\n",
    "            print(\"Failed to fetch data. Status code:\", response.status_code)\n",
    "            break\n",
    "\n",
    "# Create a DataFrame from the list of dictionaries\n",
    "df = pd.DataFrame(data_list)\n",
    "\n",
    "# Optionally, save the DataFrame to a CSV file\n",
    "df.to_csv(\"oldClinicalTrialsData.csv\", index=False)\n",
    "\n",
    "# Print the DataFrame\n",
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3.8.6 64-bit",
   "metadata": {
    "interpreter": {
     "hash": "aee8b7b246df8f9039afb4144a1f6fd8d2ca17a180786b69acc140d282b71a49"
    }
   },
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.4"
  },
  "orig_nbformat": 2
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
